# Medical Incubator Japan

> Medical Incubator Japan is a VC fund backing Biotechnology, Health Care and Life Science. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: May 2026
- Lead investor: 25%
- Last updated: Aug 2026
- Website: https://medicalincubatorjapan.com/

Medical Incubator Japan is an investment company specializing in healthcare and Comprising a group of professionals in the healthcare business and investment fields.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 3 | 38% |
| Life Science | 3 | 38% |
| Medical | 2 | 25% |
| Therapeutics | 2 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Seed | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 25% |
| Japan | 1 | 13% |
| Denmark | 1 | 13% |
| United States | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cytospire Therapeutics | Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M | Series A | May 05, 2026 |  |
| ILC Therapeutics | ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. | $3.3M | Venture - Series Unknown | Sep 11, 2024 |  |
| Hoba Therapeutics | Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain. | $24.8M | Series A | Dec 11, 2023 |  |
| Heartseed | Heartseed is a biotechnology research firm that specializes in the development of purified ventricular cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure. The company employs an innovative methodology that involves the creation of cardiomyocyte spheroids, small clusters of heart cells, using stem cells.These spheroids are then surgically implanted into the heart to improve its performance. | $14.3M | Seed | May 25, 2023 |  |
| Heartseed | Heartseed is a biotechnology research firm that specializes in the development of purified ventricular cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure. The company employs an innovative methodology that involves the creation of cardiomyocyte spheroids, small clusters of heart cells, using stem cells.These spheroids are then surgically implanted into the heart to improve its performance. | $37M | Series C | Jun 11, 2021 |  |
| Blueberry Therapeutics | Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feelbetter. Blueberry focuses on the research and development of treatments for inflammatory and infectious diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic. | $5M | Series B | Feb 16, 2021 |  |
| DiscGenics | Clinical stage biotechnology company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. | $50M | Series C | Aug 25, 2020 |  |
| ILC Therapeutics | ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis. |  |  |  |  |

8 of 8 investments shown.

## Co-investors
- [Keio Innovation Initiative](https://shizune.co/investors/profile/keio-innovations-initiative) — VC Fund, 2 deals together
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund, 2 deals together
- [Sumitomo Mitsui Trust Investment](https://shizune.co/investors/profile/sumitomo-mitsui-trust-investment) — VC Fund, 2 deals together
- [UTokyo Innovation Platform](https://shizune.co/investors/profile/utokyo-innovation-platform) — VC Fund, 2 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Unilever Ventures](https://shizune.co/investors/profile/unilever-ventures) — VC Fund
- [Fab Co-Creation Studio Ventures](https://shizune.co/investors/profile/fab-co-creation-studio-ventures) — VC Fund
- [Flybridge](https://shizune.co/investors/profile/flybridge-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Beauty VC Funds in Japan](https://shizune.co/investors/beauty-vc-funds-japan)
- [Beauty Investors in Japan](https://shizune.co/investors/beauty-investors-japan)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)

## FAQ

### What does Medical Incubator Japan invest in?

Medical Incubator Japan invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Medical Incubator Japan last invest?

The most recent investment recorded for Medical Incubator Japan closed in May 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co